A Toronto based venture capital firm founded in 2016 is investing out of its second fund, which was initially closed in October 2020 at USD 150 million. Among the 150 million, the firm manages to invest 100 million directly in companies while the other 50 million will invest in funds. The firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology (i.e., SAAS, Fintech). The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.
The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.
The firm does not have specific requirements on companies or management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply